论文部分内容阅读
丙型肝炎病毒(HCV)是输血后肝炎的主要病原,也是散发性肝炎的常见原因,感染HCV后约10～25％的患者最终发生肝硬变。由于干扰素(IFN)治疗慢性丙型肝炎的应答率较低,因此作者选用熊去氧胆酸(UDCA)与IFN联用,对慢性丙型肝炎的疗效进行了前瞻性随机对照研究。 参加本研究的80例患者(男46例,女34例)从未接受过抗病毒治疗,年龄18～70岁,ALT高出正常值上限1.5倍以上6月余,血清抗-HCV阳性,肝组织活检示慢性活动性肝炎,并排除了慢性失代偿性肝病。随机将患者分成两组:
Hepatitis C virus (HCV) is the major cause of post-transfusion hepatitis and is a common cause of sporadic hepatitis. Cirrhosis eventually occurs in about 10-25% of patients infected with HCV. Because interferon (IFN) treatment of chronic hepatitis C response rate is low, so the author selected ursodeoxycholic acid (UDCA) combined with IFN, the efficacy of chronic hepatitis C were prospective randomized controlled study. The 80 patients (46 males and 34 females) who participated in this study had never received antiviral therapy and were 18 to 70 years old. ALT was over 1.5 times the upper limit of normal for more than 6 months. Serum anti-HCV was positive, Tissue biopsies showed chronic active hepatitis and ruled out chronic decompensated liver disease. Patients were randomly divided into two groups: